Answers are grounded in this paper and cite their sources.
Retrospective analysis demonstrates that venetolax plus azacitidine improves outcomes in intermediate/high-risk AML post-allogeneic transplantation, indicating effective maintenance therapy.
Background: Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with intermediate/high-risk acute myeloid leukemia (AML) remains a major cause of treatment failure and associated poor outcomes. Evidence regarding the venetolax plus azacytidine (VEN+AZA) as a prevent relapse therapy for patients with intermediate/high-risk AML after allo-HSCT is scare. Patients and methods: We retrospectively evaluated the outcome of VEN+AZA (n=23) as maintenance therapy to prevent relapse after allo-HSCT for patients with intermediate/high-risk AML enrolled from January 2020 to April 2023, and compared with patients not received any anti-AML therapy as maintenance therapy after allo-HSCT as control group (n=59) (September 2013 - April 2023) in our center. All patients in VEN+AZA group received VEN (200mg/d, on day 1 to 28) and AZA (100mg/d, on day 1 to 5) from 3 months after transplantation. The cycle interval was 1 months, and there were 9 cycles. Patients in the history cohort were not received any anti-AML therapy as maintenance therapy after allo-HSCT. The cumulative incidence of relapse was estimated using competing-risk methods. The probabilities of survival outcomes were calculated according to the Kaplan-Meier method and compared using the long-rank test. Results: The median age of patients in the VEN+AZA group (36 years, [range, 16-63]) compared with control group (35 years, [ranges, 13-57], p=0.706). No significant differences were observed in baseline data, including sex, risk stratification, donor-recipient relationship between two groups. Compared with the control group, the cumulative incidence of relapse was significantly lower in the VEN+AZA group (8.7±6.0% vs. 37.3±6.4%, p=0.029) after transplantation. Overall survival (OS) at three years was better with VEN+AZA group (94.1±5.7%) than control group (61.3±7.0%, p=0.045). Nonrelapse mortality (NRM) at three years in VA group (82.4±12.1%) was also significantly superior to control group (46.5±7.1%, p=0.034). Conclusions: Our data indicate that patients with intermediate/high-risk AML after allo-HSCT received VEN+AZA therapy decreases the relapse rate, and yields better OS and NRM. The role of VEN+AZA as a potential treatment to prevent relapse in intermediate/high-risk AML should be considered.
No takes yet. Share an insight, caveat, or question.
Xiaoxuan Xu (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: